Psoriasis

Bio-Thera Solutions Expands Partnership with Pharmapark in Russia and other CIS Countries with Addition of BAT2206, a Stelara® Biosimilar

Friday, October 15, 2021 - 1:08pm

Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.

Key Points: 
  • Bio-Thera and Pharmaparks partnership was initiated around a licensing and supply agreement for Pharmapark to distribute and market BAT2506, a golimumab biosimilar, in Russia and other CIS countries.
  • Pharmapark will be responsible for filing the dossier in Russia and other CIS countries.
  • This partnership will leverage Pharmaparks strong local presence, sales and marketing capabilities in Russia and other CIS countries.
  • Bio-Thera is pleased to expand our partnership with Pharmapark to commercialize our ustekinumab biosimilar program in Russia and other CIS countries, said Dr. Shengfeng Li, CEO of Bio-Thera.

New Data Presented at ECTRIMS Show Evobrutinib is First BTK Inhibitor to Demonstrate a Significant Reduction in Slowly Expanding Lesions (SEL) in Patients with RMS

Thursday, October 14, 2021 - 4:00pm

Evobrutinib reduced SEL volume compared to placebo in a dose-dependent manner with the highest effect with 75mg twice daily (p=0.047).

Key Points: 
  • Evobrutinib reduced SEL volume compared to placebo in a dose-dependent manner with the highest effect with 75mg twice daily (p=0.047).
  • In a subgroup analysis, the effect of evobrutinib on SEL volume was also especially apparent in patients with more advanced disease.
  • These results, combined with the reduction in Gd+ lesions reported previously, suggest that evobrutinib reduces both acute and chronic neuroinflammation that together lead to worsening disability.
  • These initial findings across NfL data combined with SEL data continue to show evobrutinibs potential benefit in disease progression.

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following FDA Acceptance of Investigational New Drug Application for Phase 1 Clinical Trial in Non-Hodgkin’s Lymphoma

Thursday, October 14, 2021 - 1:00pm

Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.

Key Points: 
  • Exelixis has now assumed responsibility for the future clinical development, commercialization and global manufacturing of XL114.
  • Following the U.S. Food and Drug Administrations (FDA) recent acceptance of its Investigational New Drug (IND) application, Exelixis will soon initiate a phase 1 clinical trial evaluating XL114 monotherapy in patients with Non-Hodgkins lymphoma (NHL).
  • View the full release here: https://www.businesswire.com/news/home/20211014005549/en/
    XL114 is the second molecule that Exelixis in-licensed from Aurigene under the companies July 2019 collaboration, option and license agreement.
  • Exelixis, the Exelixis logo, CABOMETYX, COMETRIQ and COTELLIC are registered trademarks of Exelixis, Inc. MINNEBRO is a registered trademark of Daiichi Sankyo Company, Limited.

DGAP-News: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 12:08pm

NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.

Key Points: 
  • NEW YORK, October 14, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, announced the appointment of Patrick Walsh as Chief Business Officer, effective today.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

ASLAN Pharmaceuticals Announces Expansion of Scientific Advisory Board With Appointment of Leading Global Experts in Dermatology and Immunology

Thursday, October 14, 2021 - 12:00pm

The SAB, chaired by Dr Lawrence Eichenfield, MD FAAD, was established in September following the appointment of Dr Eichenfield and Dr Eric Simpson, MD MCR.

Key Points: 
  • The SAB, chaired by Dr Lawrence Eichenfield, MD FAAD, was established in September following the appointment of Dr Eichenfield and Dr Eric Simpson, MD MCR.
  • Dr Melinda Gooderham is the Medical Director at the SKiN Centre for Dermatology and an Investigator with Probity Medical Research, Ontario, Canada.
  • Associate Professor Peter Foley is Head, Dermatology Research, Department of Dermatology at St Vincents Hospital, Melbourne.
  • Dr Ken Kobayashi, Chief Medical Officer, ASLAN Pharmaceuticals, commented: We are delighted to welcome Melinda, Jacob and Peter to our Scientific Advisory Board.

Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer

Thursday, October 14, 2021 - 11:30am

In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.

Key Points: 
  • In this newly created role, Mr. Walsh will be responsible for business development, including strategic partnering opportunities, and will become part of the executive management team of Immunic.
  • "Patrick is a seasoned business development executive who has spent his career helping to successfully build a number of public biopharmaceutical companies.
  • He brings to Immunic extensive leadership in building companies through strategic partnerships and non-dilutive funding," stated Daniel Vitt, Ph.D., Chief Executive Officer and President of Immunic.
  • Mr. Walsh was previously in Corporate Development at AVEO Oncology, during which time he worked on all aspects of business development.

Abcentra Appoints Entrepreneur and Cardiologist Michael H. Davidson to Board of Directors

Thursday, October 14, 2021 - 10:37am

LOS ANGELES, Oct. 14, 2021 /PRNewswire/ -- Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.

Key Points: 
  • LOS ANGELES, Oct. 14, 2021 /PRNewswire/ -- Abcentra LLC announced today that Michael H. Davidson, MD, has been appointed to the Board of Directors.
  • "Millions of patients are at risk of a cardiovascular event because of inflammation, even after maximal lipid lowering," said Dr. Davidson.
  • "This residual inflammatory risk is particularly evident in the psoriasis, rheumatoid arthritis, and lupus populations, where Abcentra is focusing its initial development of orticumab.
  • Dr. Davidson received his BA/MS from Northwestern University and MD from The Ohio State University School of Medicine.

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

Thursday, October 14, 2021 - 7:40am

HELLERUP, Denmark, Oct. 14, 2021 /PRNewswire/ -- UNION therapeutics A/S, a privately-held, multi-asset, clinical stage, pharmaceutical company focused on immunology and infectious diseases, today announced the enrollment of the first patient in OSIRIS, a Phase 2, open-label, proof of concept study of an oral tablet formulation of orismilast in adult patients with mild, moderate, and severe HS. The primary objective of OSIRIS is to explore evidence of efficacy of oral orismilast in the treatment of patients with HS for up to 16 weeks. Orismilast is currently in Phase 2 of clinical development for various inflammatory skin diseases, including psoriasis and atopic dermatitis.

Key Points: 
  • The primary objective of OSIRIS is to explore evidence of efficacy of oral orismilast in the treatment of patients with HS for up to 16 weeks.
  • Orismilast is currently in Phase 2 of clinical development for various inflammatory skin diseases, including psoriasis and atopic dermatitis.
  • The study will enroll 24 adult patients (men and women); 8 with mild, 8 with moderate, and 8 with severe HS.
  • Treatment for HS patients typically includes topical, oral or intravenous antibiotic treatment, which often provide only temporary symptomatic relief.

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

Thursday, October 14, 2021 - 7:32am

The primary objective of OSIRIS is to explore evidence of efficacy of oral orismilast in the treatment of patients with HS for up to 16 weeks.

Key Points: 
  • The primary objective of OSIRIS is to explore evidence of efficacy of oral orismilast in the treatment of patients with HS for up to 16 weeks.
  • Orismilast is currently in Phase 2 of clinical development for various inflammatory skin diseases, including psoriasis and atopic dermatitis.
  • The study will enroll 24 adult patients (men and women); 8 with mild, 8 with moderate, and 8 with severe HS.
  • Treatment for HS patients typically includes topical, oral or intravenous antibiotic treatment, which often provide only temporary symptomatic relief.

Global Biologics Market Research Report 2021-2026 - Rising Demand for Biologics in Treatment of Chronic Diseases - ResearchAndMarkets.com

Wednesday, October 13, 2021 - 12:54pm

The "Global Biologics Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Biologics Market Research Report: Forecast (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
  • Moreover, regulatory approval from the governments in different countries is also contributing to the growth of the Biologics market.
  • What are the overall market statistics or estimates (Market Overview, Market Size - by Value, Forecast Numbers, Market Segmentation, and Market Shares) of the Global Biologics Market?
  • What are the key results derived from the market surveys conducted during the Global Biologics Market study?